Contraceptive Technology Update – November 1, 2009
November 1, 2009
View Issues
-
HPV vaccine update: Will there be more options for women and men?
Get set for possible changes in human papillomavirus (HPV) vaccine use. A Food and Drug Administration (FDA) review committee has voted that clinical data support the efficacy and safety of GlaxoSmithKline's Cervarix vaccine candidate for the prevention of cervical precancers and cervical cancer related to HPV types 16 and 18 in girls and young women. -
Review data on Pill use and thrombosis risk
Despite the findings of two new studies,1,2 providers should focus on the fact that two earlier, large studies have compared safety data from women using Yasmin (Bayer HealthCare Pharmaceuticals; Wayne, NJ) to that of other oral contraceptive (OC) users,3,4 family planning experts emphasize. -
Rapid chlamydia test for men examined
Research of an experimental urine test indicates that it successfully diagnoses chlamydia infection in men within the hour, which improves the ability to successfully treat the infection on the spot and prevent retransmission. -
New data emerge on emergency contraception
Family planning clinicians have new research information to add to their emergency contraception (EC) knowledge bank as they incorporate use of two new branded products into their practice. -
Science eyes new forms of barrier protection
In 2007, the Centers for Disease Control and Prevention reported that 26% of HIV/AIDS diagnoses among adolescents and adults were among females. -
Teen Topics: What's the state of teen reproductive health?
In July 2009, data from the National Vital Statistics System were published presenting a snapshot of the sexual and reproductive health of young people aged 10-24 between 2002 and 2007.